143 related articles for article (PubMed ID: 33952778)
1. Generic selection criteria for safety and patient benefit [X]: Water-vapor permeability and peel force properties of brand-name and generic ketoprofen tapes.
Nozawa M; Goto M; Wada Y; Ishii F; Shimokawa KI
Drug Discov Ther; 2021 May; 15(2):87-92. PubMed ID: 33952778
[TBL] [Abstract][Full Text] [Related]
2. Generic Selection Criteria for Safety and Patient Benefit [IV] - Physicochemical and pharmaceutical properties of brand-name and generic ketoprofen tapes.
Wada Y; Kihara M; Nozawa M; Shimokawa K; Ishii F
Drug Discov Ther; 2015 Jun; 9(3):229-33. PubMed ID: 26193946
[TBL] [Abstract][Full Text] [Related]
3. [Prediction of systemic exposure of ketoprofen tapes by in vitro release test and pharmacokinetic model analysis: comparison between brand-name and generic formulations].
Awa K; Satoh H; Hori S; Sawada Y
Yakugaku Zasshi; 2012; 132(1):135-44. PubMed ID: 22214588
[TBL] [Abstract][Full Text] [Related]
4. Generic selection criteria for safety and patient benefit [VIII]: Comparing the physicochemical and pharmaceutical properties of brand-name and generic diclofenac sodium tapes.
Nozawa M; Goto M; Wada Y; Yotsukura K; Gannichida A; Ishii F; Shimokawa KI
Drug Discov Ther; 2019 Jul; 13(3):150-156. PubMed ID: 31257355
[TBL] [Abstract][Full Text] [Related]
5. Generic selection criteria for safety and patient benefit [VI]: Comparing the physicochemical and pharmaceutical properties of brand-name, generic, and OTC felbinac tapes.
Wada Y; Takaoka Y; Nozawa M; Goto M; Shimokawa KI; Ishii F
Drug Discov Ther; 2017 Jan; 10(6):300-306. PubMed ID: 27725574
[TBL] [Abstract][Full Text] [Related]
6. Generic selection criteria for safety and patient benefit [Ⅻ]: Comparing the physicochemical and pharmaceutical properties of brand-name and generic tulobuterol tape.
Shimokawa KI; Yotsukura K; Nozawa M; Wada Y; Ishii F
Drug Discov Ther; 2024 Jan; 17(6):409-414. PubMed ID: 38044119
[TBL] [Abstract][Full Text] [Related]
7. [Questionnaire survey of patients comparing the usability of brand-name and generic ketoprofen tapes].
Saita A; Inoue A; Ishibashi H; Tominaga K; Hori S; Miki A; Ohtani H; Ono N; Sawada Y
Yakugaku Zasshi; 2008 May; 128(5):795-803. PubMed ID: 18451628
[TBL] [Abstract][Full Text] [Related]
8. [Effect of Adhesives on the Properties of Adhesion, Drug Release and Skin Permeation of Lidocaine Tapes].
Sugino M; Mikami M; Ishihara T; Hosoya O; Juni K
Yakugaku Zasshi; 2015; 135(8):977-85. PubMed ID: 26234356
[TBL] [Abstract][Full Text] [Related]
9. Generic selection criteria for safety and patient benefit [XI]: Usability scores of brand-name and generic tapes containing sodium diclofenac by questionnaire survey.
Nozawa M; Gannichida A; Wada Y; Kumazawa M; Ishii F; Shimokawa KI
Drug Discov Ther; 2022 Nov; 16(5):210-216. PubMed ID: 36261340
[TBL] [Abstract][Full Text] [Related]
10. Molecular State of Active Pharmaceutical Ingredients in Ketoprofen Dermal Patches Characterized by Pharmaceutical Evaluation.
Azuma M; Fujii M; Inoue M; Hisada H; Koide T; Kemper M; Yamamoto Y; Suzuki N; Suzuki T; Fukami T
Biol Pharm Bull; 2018; 41(9):1348-1354. PubMed ID: 30175772
[TBL] [Abstract][Full Text] [Related]
11. Transdermal Adhesive Patches Loaded with Ketoprofen Evaluated by Dynamic Detection of Percutaneous Absorption.
Wang M; Li L; Xie J; Sun Y; Ling G; He Z
AAPS PharmSciTech; 2017 Aug; 18(6):2141-2148. PubMed ID: 28035612
[TBL] [Abstract][Full Text] [Related]
12. Generic selection criteria for safety and patient benefit [VII]: Comparing the physicochemical and pharmaceutical properties of brand-name and generic terbinafine hydrochloride cream.
Nozawa M; Goto M; Wada Y; Kumazawa M; Shimokawa KI; Ishii F
Drug Discov Ther; 2018 Mar; 12(1):16-20. PubMed ID: 29479048
[TBL] [Abstract][Full Text] [Related]
13. Transdermal enhancement strategy of ketoprofen and teriflunomide: The effect of enhanced drug-drug intermolecular interaction by permeation enhancer on drug release of compound transdermal patch.
Liu C; Guan Y; Tian Q; Shi X; Fang L
Int J Pharm; 2019 Dec; 572():118800. PubMed ID: 31678378
[TBL] [Abstract][Full Text] [Related]
14. Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations.
Cevc G; Mazgareanu S; Rother M; Vierl U
Int J Pharm; 2008 Jul; 359(1-2):190-7. PubMed ID: 18499370
[TBL] [Abstract][Full Text] [Related]
15. Elimination of ketoprofen from the stratum corneum after topical administration with ketoprofen formulations in human subjects.
Takeshi M; Ebihara T; Maekawa K; Yamamoto K; Higo N
Int J Pharm; 2014 Apr; 465(1-2):197-201. PubMed ID: 24530385
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous optimization of percutaneous delivery and adhesion for ketoprofen poultice.
Sheu MT; Chen LC; Ho HO
Int J Pharm; 2002 Feb; 233(1-2):257-62. PubMed ID: 11897430
[TBL] [Abstract][Full Text] [Related]
17. [Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes].
Izumi T; Hori S; Satoh H; Miki A; Sawada Y
Yakugaku Zasshi; 2012; 132(5):617-27. PubMed ID: 22687698
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Water Content and Skin Permeability of Active Pharmaceutical Ingredients in Ketoprofen Poultice Formulations Removed from Their Airtight Containers and Left at Room Temperature.
Yamamoto Y; Yamauchi R; Ohno S; Asai K; Fukami T; Koide T
Biol Pharm Bull; 2019; 42(12):2102-2108. PubMed ID: 31787725
[TBL] [Abstract][Full Text] [Related]
19. Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles.
Nagai N; Ogata F; Ishii M; Fukuoka Y; Otake H; Nakazawa Y; Kawasaki N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041452
[TBL] [Abstract][Full Text] [Related]
20. Enhanced transdermal delivery of ketoprofen from bioadhesive gels.
Singh S; Gajra B; Rawat M; Muthu MS
Pak J Pharm Sci; 2009 Apr; 22(2):193-8. PubMed ID: 19339232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
